Pancreatic Cancer Research

ResearcherKansai Medical UniversityActive in the last 2 years

So Yamaki

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6178-7984; OpenAlex author ID A5040347472. Sources: OpenAlex.

Their work

Papers
49
Trials
0
Grants
0
Labs led
0
Collaborators
111
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 5 papers · 2017: 3 papers · 2018: none · 2019: 2 papers · 2020: 4 papers · 2021: 4 papers · 2022: 4 papers · 2023: 7 papers · 2024: 3 papers · 2025: 4 papers · 2026: 5 papers

Papers 49

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  3. Survival Impact of Pathological Residual Patterns for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. Co-author DOI 10.1002/jhbp.70146↗
  4. Neoadjuvant and adjuvant treatment for pancreatic ductal adenocarcinoma in patients over 80 years old based on a nationwide clinical database. Co-author DOI 10.1007/s00535-026-02480-8↗
  5. Fecal Bifidobacterium Serves as a Predictor of Postoperative Recurrence After Neoadjuvant Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1016/j.gastha.2025.100779↗
  6. Clinical role of intraperitoneal chemotherapy in patients with pancreatic ductal adenocarcinoma concomitant with occult peritoneal dissemination: A multicenter… Co-author DOI 10.1002/ags3.70001↗
  7. Long-term outcomes of prophylactic right-half dissection of the superior mesenteric artery nerve plexus in pancreatoduodenectomy for pancreatic ductal adenocar… Co-author DOI 10.1007/s00595-025-03062-6↗
  8. Neoadjuvant Treatment with Changes in Chemotherapy Regimens According to Carbohydrate Antigen 19-9 Level for Resectable/Borderline Resectable Pancreatic Ductal… Co-author DOI 10.1245/s10434-024-16361-y↗
  9. Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18084-0↗
  10. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clini… Co-author DOI 10.1016/j.pan.2024.03.012↗
  11. Impact of endoscopic ultrasound-guided tissue acquisition on prognosis and peritoneal lavage cytology in resectable or borderline resectable pancreatic ductal … Co-author DOI 10.1016/j.pan.2024.06.001↗
  12. Conversion surgery for BRCA-mutated pancreatic ductal adenocarcinoma with liver metastasis treated with platinum-based chemotherapy followed by olaparib. Co-author DOI 10.1186/s40792-024-01975-x↗
  13. Reevaluation of regional lymph nodes in patients with pancreatic ductal adenocarcinoma in the pancreatic body and tail. Co-author DOI 10.1002/ags3.12608↗
  14. Survival impact of occult liver metastasis and peritoneal dissemination compared with radiologically defined distant organ metastasis in pancreatic ductal aden… Co-author DOI 10.1016/j.pan.2022.11.012↗
  15. Impact of neoadjuvant therapy on gut microbiome in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2023.04.001↗
  16. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery… Co-author DOI 10.1016/j.pan.2023.07.005↗
  17. Efficacy of Lentinula edodes Mycelia Extract on Chemotherapy-Related Tasted Disorders in Pancreatic Cancer Patients. Co-author DOI 10.1080/01635581.2022.2107226↗
  18. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospectiv… Co-author DOI 10.21037/jgo-23-655↗
  19. A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer. Co-author DOI 10.3390/jcm12103477↗
  20. A simple risk score for detecting radiological occult metastasis in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jhbp.1026↗
  21. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Co-author DOI 10.1002/jhbp.1085↗
  22. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… Co-author DOI 10.1186/s13063-022-06049-7↗
  23. Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit. Co-author DOI 10.3390/cancers14051354↗
  24. Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therap… Co-author DOI 10.1007/s00595-021-02308-3↗
  25. Does direct invasion of peripancreatic lymph nodes impact survival in patients with pancreatic ductal adenocarcinoma? A retrospective dual-center study. Co-author DOI 10.1016/j.pan.2021.03.008↗
  26. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.21037/jgo-20-243↗
  27. Clinicopathological characteristics of pancreatic ductal adenocarcinoma with invasive micropapillary carcinoma component with emphasis on the usefulness of PKC… Co-author DOI 10.3892/ol.2021.12786↗
  28. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ags3.12295↗
  29. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.1002/bjs.11792↗
  30. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00595-020-01963-2↗
  31. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12061428↗
  32. Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis. Co-author DOI 10.1016/j.pan.2019.03.001↗
  33. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2018-0900↗
  34. Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospectiv… Co-author DOI 10.1002/jhbp.447↗
  35. Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy. Co-author DOI 10.1007/s00595-016-1358-9↗
  36. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive de… Co-author DOI 10.1007/s10147-017-1112-3↗
  37. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreati… Co-author DOI 10.1002/jhbp.318↗
  38. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal ade… Co-author DOI 10.1002/jhbp.408↗
  39. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic … Co-author DOI 10.1007/s00280-015-2928-z↗
  40. Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarc… Co-author DOI 10.1080/01635581.2016.1134597↗
  41. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-016-0767-y↗
  42. Potential role of surgical resection for pancreatic cancer in the very elderly. Co-author DOI 10.1016/j.pan.2015.03.015↗
  43. Role of adjuvant surgery in initially unresectable pancreatic cancer after long-term chemotherapy or chemoradiation therapy: survival benefit? Co-author DOI 10.1002/jhbp.119↗
  44. Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000125↗
  45. Activation of alpha-smooth muscle actin-positive myofibroblast-like cells after chemotherapy with gemcitabine in a rat orthotopic pancreatic cancer model. Co-author DOI 10.1007/s00534-012-0576-9↗
  46. Long-term results of surgical resection after preoperative chemoradiation in patients with pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e318229758f↗
  47. Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e3182373a66↗
  48. Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderlin… Co-author DOI 10.1097/mpa.0b013e3182056b1c↗
  49. The role of circulating dendritic cells in patients with unresectable pancreatic cancer. Co-author PMID 22110205↗

Closest collaborators

The 25 strongest of 111 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sohei Satoi · 47 shared papers, 2011–2026 · strength 5.84
  2. Daisuke Hashimoto · 25 shared papers, 2021–2026 · strength 4.40
  3. Tomohisa Yamamoto · 38 shared papers, 2011–2025 · strength 3.87
  4. Mitsugu Sekimoto · 17 shared papers, 2020–2025 · strength 2.58
  5. Satoshi Hirooka · 24 shared papers, 2011–2023 · strength 1.89
  6. Tsukasa Ikeura · 10 shared papers, 2022–2026 · strength 1.72
  7. Yuki Matsui · 8 shared papers, 2022–2026 · strength 1.63
  8. Hiroaki Yanagimoto · 21 shared papers, 2011–2023 · strength 1.38
  9. Hidetaka Miyazaki · 5 shared papers, 2024–2026 · strength 1.12
  10. Fuyuhiko Motoi · 7 shared papers, 2020–2026 · strength 1.08
  11. Masamichi Mizuma · 5 shared papers, 2025–2026 · strength 1.01
  12. Tsutomu Fujii · 7 shared papers, 2020–2025 · strength 0.97
  13. Michiaki Unno · 5 shared papers, 2022–2026 · strength 0.94
  14. Satoshi Hirano · 6 shared papers, 2020–2026 · strength 0.91
  15. Hironori Ryota · 11 shared papers, 2016–2021 · strength 0.91
  16. Atsushi Oba · 5 shared papers, 2023–2026 · strength 0.90
  17. Tatsuma Sakaguchi · 6 shared papers, 2020–2023 · strength 0.85
  18. Koh Nakamaru · 5 shared papers, 2022–2026 · strength 0.82
  19. Denys Tsybulskyi · 4 shared papers, 2023–2026 · strength 0.81
  20. Kenichiro Uemura · 4 shared papers, 2022–2026 · strength 0.72
  21. Takashi Ito · 4 shared papers, 2023–2026 · strength 0.69
  22. Makoto Naganuma · 4 shared papers, 2023–2026 · strength 0.69
  23. Nobuhiko Nakagawa · 3 shared papers, 2025–2026 · strength 0.65
  24. Teiichi Sugiura · 3 shared papers, 2025–2026 · strength 0.60
  25. Kenjiro Okada · 3 shared papers, 2025–2026 · strength 0.60

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.